Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Stroma-targeted palliative tumor therapy with biomodulators].

Christian Hafner1, Michael Landthaler, Thomas Vogt

  • 1Klinik und Poliklinik für Dermatologie, Universität Regensburg.

Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|April 22, 2006
PubMed
Summary

New biomodulating drugs target tumor stroma for advanced cancer therapy. Combination therapies show promise for palliative care, offering mild side effects and patient acceptance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Person-centered wound care : Legitimation and theoretical concept].

Zeitschrift fur Gerontologie und Geriatrie·2025
Same author

Pioneers in Dermatology and Venereology: An interview with Professor Michael Landthaler.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab.

PloS one·2025
Same author

Degree of Actinic Elastosis Is a Surrogate of Exposure to Chronic Ultraviolet Radiation and Correlates More Strongly with Cutaneous Squamous Cell Carcinoma than Basal Cell Carcinoma.

Life (Basel, Switzerland)·2023
Same author

Phototherapy-induced elevation of serum level of melanoma inhibitory activity.

Photodermatology, photoimmunology & photomedicine·2019
Same author

Atomic Scale Photodetection Enabled by a Memristive Junction.

ACS nano·2018

Area of Science:

  • Oncology
  • Tumor Microenvironment Research
  • Pharmacology

Background:

  • Advanced tumors present therapeutic challenges, necessitating novel treatment strategies.
  • Stroma-targeted approaches, particularly antiangiogenic therapies, are emerging as promising avenues.
  • Certain biomodulating drugs, initially developed for non-oncologic indications, demonstrate significant antitumor effects.

Purpose of the Study:

  • To explore the potential of biomodulating drugs in targeting tumor stroma for advanced cancer therapy.
  • To evaluate the efficacy of combining these drugs for enhanced antitumor activity.
  • To assess the role of these agents as supplementary or alternative palliative treatments.

Main Methods:

  • Review of existing literature on biomodulating drugs with anti-stromal effects.

Related Experiment Videos

  • Analysis of drug classes including thalidomide, COX-2 inhibitors, PPARgamma agonists, and mTOR antagonists.
  • Evaluation of combination therapy strategies and their impact on tumor stroma.

    • Main Results:

    • Biomodulating drugs like thalidomide, COX-2 inhibitors, PPARgamma agonists (thiazolidindiones), and mTOR antagonists (rapamycin) exert antitumor effects via indirect actions on tumor stroma.
    • Combination therapies involving these agents appear more effective than monotherapies.
    • These therapies offer a viable option for palliative treatment of advanced tumors.

    Conclusions:

    • Biomodulating drugs targeting tumor stroma represent a novel strategy for advanced cancer palliation.
    • Combination therapy with these agents can enhance efficacy and patient outcomes.
    • These approaches are well-tolerated, suitable for outpatient settings, and complement existing treatments.